You are here: Industry Insights > Menarini

News List

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer PRNewswire
December 12, 2024
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories prnasia
December 22, 2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group, ("Menarini"), a privately-held...
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021 prnasia
December 13, 2021
The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RDUS) (collectively, the "Companies") provided details on the elacestrant data from the EMERALD trial following the positive results presented today...
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia prnasia
November 05, 2021
The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML).
Menarini Asia-Pacific strengthens Men's Health portfolio in China with acquisition of Cialis(R) (Tadalafil) from Lilly prnasia
July 22, 2021
A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the Menarini Group, the world's largest Italian biopharmaceutical company, announced today the completion of its acquisition of Cialis® in the People's Republic of China from Eli Lilly and Company.
Glenmark Pharma and Menarini enter into exclusive licensing agreement for commercialising Ryaltris for European markets expresspharma
December 23, 2020
Glenmark will receive an upfront payment as well as launch and sales based milestone payments from Menarini for Ryaltris sales.
Menarini to buy Stemline for up to $677 million pharmatimes
May 05, 2020
Menarini is to purchase Stemline Therapeutics in a deal valued at up to $677 million, establishing its presence in the US biopharma market.
Menarini Hires Their 17,000th Employee prnasia
March 14, 2018
The 17,000th employee at Menarini is Lara, 28 years old, a young graduate in Chemistry and Pharmaceutical Technology from the University of Florence, who is now employed in Menarini Ricerche.
Pharma companies fall foul of ABPI’s Code of Practice pharmatimes
December 14, 2017
Sunovion Pharmaceuticals Europe, Bayer, Astellas UK, Astellas Europe and Menarini Pharma UK SRL have been named in adverts for breaching of the ABPI’s Code of Practice.